Avatrombopag

Therapeutic indications

Avatrombopag is indicated for:

Severe thrombocytopenia with chronic liver disease

Population group: both men and women, only adults (18 - 65 years old)

Avatrombopag is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

40-60 mg in 2-3 divided doses daily

Primary chronic immune thrombocytopenia (ITP)

Population group: both men and women, only adults (18 - 65 years old)

Avatrombopag is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

20 mg once daily

< Previous: Overview

Next: Precautions >